Expression and Role of RIP140/NRIP1 in Chronic Lymphocytic Leukemia

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2015 Apr 17

PMID 25879677

Citations 16

Authors

Marion Lapierre

Audrey Castet-Nicolas

Delphine Gitenay

Stephan Jalaguier

Catherine Teyssier

Caroline Bret

Guillaume Cartron

Jerome Moreaux

Vincent Cavailles

Affiliations

Soon will be listed here.

Abstract

RIP140 is a transcriptional coregulator, (also known as NRIP1), which finely tunes the activity of various transcription factors and plays very important physiological roles. Noticeably, the RIP140 gene has been implicated in the control of energy expenditure, behavior, cognition, mammary gland development and intestinal homeostasis. RIP140 is also involved in the regulation of various oncogenic signaling pathways and participates in the development and progression of solid tumors. During the past years, several papers have reported evidences linking RIP140 to hematologic malignancies. Among them, two recent studies with correlative data suggested that gene expression signatures including RIP140 can predict survival in chronic lymphocytic leukemia (CLL). This review aims to summarize the literature dealing with the expression of RIP140 in CLL and to explore the potential impact of this factor on transcription pathways which play key roles in this pathology.

Citing Articles

A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma.

Liu Y, Zhang H, Zhao S, Zhang Y Clin Transl Oncol. 2024; 26(12):2966-2978.

PMID: 38773060 PMC: 11564284. DOI: 10.1007/s12094-024-03515-3.

Determinants of mosaic chromosomal alteration fitness.

Pershad Y, Mack T, Poisner H, Jakubek Y, Stilp A, Mitchell B Nat Commun. 2024; 15(1):3800.

PMID: 38714703 PMC: 11076528. DOI: 10.1038/s41467-024-48190-8.

Methylation of NRIP3 Is a Synthetic Lethal Marker for Combined PI3K and ATR/ATM Inhibitors in Colorectal Cancer.

Zhang M, Li X, Herman J, Gao A, Wang Q, Yao Y Clin Transl Gastroenterol. 2024; 15(3):e00682.

PMID: 38235705 PMC: 10962901. DOI: 10.14309/ctg.0000000000000682.

A survival prediction model and nomogram based on immune-related gene expression in chronic lymphocytic leukemia cells.

Huang H, Wang Y, Herold T, Gale R, Wang J, Li L Front Med (Lausanne). 2023; 9:1026812.

PMID: 36600891 PMC: 9806429. DOI: 10.3389/fmed.2022.1026812.

Whole-genome sequencing in diverse subjects identifies genetic correlates of leukocyte traits: The NHLBI TOPMed program.

Mikhaylova A, McHugh C, Polfus L, Raffield L, Boorgula M, Blackwell T Am J Hum Genet. 2021; 108(10):1836-1851.

PMID: 34582791 PMC: 8546043. DOI: 10.1016/j.ajhg.2021.08.007.

References

Ho P, Tsui Y, Feng X, Greaves D, Wei L . NF-κB-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance. Nat Immunol. 2012; 13(4):379-86. PMC: 3309172. DOI: 10.1038/ni.2238. View

Docquier A, Harmand P, Fritsch S, Chanrion M, Darbon J, Cavailles V . The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes. Clin Cancer Res. 2010; 16(11):2959-70. PMC: 3112174. DOI: 10.1158/1078-0432.CCR-09-3153. View

Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2009; 10(1):37-50. DOI: 10.1038/nrc2764. View

Cavailles V, Dauvois S, LHorset F, Lopez G, Hoare S, Kushner P . Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 1995; 14(15):3741-51. PMC: 394449. DOI: 10.1002/j.1460-2075.1995.tb00044.x. View

Zhang R, Kim Y, Yang X, Li Y, Li S, Lee J . A possible 5'-NRIP1/UHRF1-3' fusion gene detected by array CGH analysis in a Ph+ ALL patient. Cancer Genet. 2012; 204(12):687-91. DOI: 10.1016/j.cancergen.2011.11.006. View

Gutierrez Jr A, Tschumper R, Wu X, Shanafelt T, Eckel-Passow J, Huddleston 3rd P . LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood. 2010; 116(16):2975-83. PMC: 2974605. DOI: 10.1182/blood-2010-02-269878. View

Lu D, Zhao Y, Tawatao R, Cottam H, Sen M, Leoni L . Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004; 101(9):3118-23. PMC: 365753. DOI: 10.1073/pnas.0308648100. View

Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N . Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol. 2004; 22(19):3937-49. DOI: 10.1200/JCO.2004.12.133. View

Vant Veer M, Brooijmans A, Langerak A, Verhaaf B, Goudswaard C, Graveland W . The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica. 2006; 91(1):56-63. View

10.

Zschiedrich I, Hardeland U, Krones-Herzig A, Diaz M, Vegiopoulos A, Muggenburg J . Coactivator function of RIP140 for NFkappaB/RelA-dependent cytokine gene expression. Blood. 2008; 112(2):264-76. DOI: 10.1182/blood-2007-11-121699. View

11.

Simonsson B, Terenius L, Nilsson K . Glucocorticoid receptors, clinical characteristics, and implications for prognosis in chronic lymphocytic leukemia. Cancer. 1982; 49(12):2493-6. DOI: 10.1002/1097-0142(19820615)49:12<2493::aid-cncr2820491214>3.0.co;2-b. View

12.

Hasserjian R . Acute myeloid leukemia: advances in diagnosis and classification. Int J Lab Hematol. 2013; 35(3):358-66. DOI: 10.1111/ijlh.12081. View

13.

Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas J, Sanchez A, Martin-Saavedra F . A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004; 18(8):1391-400. DOI: 10.1038/sj.leu.2403398. View

14.

Chiorazzi N, Rai K, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8):804-15. DOI: 10.1056/NEJMra041720. View

15.

Huang T, Hsieh J, Wu Y, Jen C, Tsuang Y, Chiou S . Functional network reconstruction reveals somatic stemness genetic maps and dedifferentiation-like transcriptome reprogramming induced by GATA2. Stem Cells. 2008; 26(5):1186-201. DOI: 10.1634/stemcells.2007-0821. View

16.

Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M . The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood. 2005; 106(2):650-7. DOI: 10.1182/blood-2004-08-3344. View

17.

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56. PMC: 2972576. DOI: 10.1182/blood-2007-06-093906. View

18.

Aggarwal R, Lu J, Pompili V, Das H . Hematopoietic stem cells: transcriptional regulation, ex vivo expansion and clinical application. Curr Mol Med. 2011; 12(1):34-49. PMC: 3286491. DOI: 10.2174/156652412798376125. View

19.

Maffei R, Bulgarelli J, Fiorcari S, Martinelli S, Castelli I, Valenti V . Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. PLoS One. 2014; 9(6):e98818. PMC: 4046988. DOI: 10.1371/journal.pone.0098818. View

20.

Forsberg E, Passegue E, Prohaska S, Wagers A, Koeva M, Stuart J . Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS One. 2010; 5(1):e8785. PMC: 2808351. DOI: 10.1371/journal.pone.0008785. View